Searchable abstracts of presentations at key conferences in endocrinology

ea0026p643 | Clinical case reports | ECE2011

Bexarotene associated dyslipidaemia and central hypothyroidism in a patient with Sézary syndrome

Alves M , Neves C , Azevedo F , Correia O , Carvalho-Braga D , Carvalho D

Background: Sézary syndrome (SS) is a more aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL). Bexarotene (Targretin) is a synthetic rexinoid analogue designed for the treatment of advanced stages of cutaneous manifestations of CTLC. Bexarotene selectively suppresses thyrotropin secretion and up to 40% of patients develop reversible idiopatic central hypothyroidism. Severe mixed dyslipidemia may be present in up to 70%.Case report: Seve...